Bayer (FRA:BAYN)‘s stock had its “buy” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday.
A number of other analysts have also commented on BAYN. Baader Bank set a €140.00 ($162.79) price objective on Bayer and gave the company a “buy” rating in a research note on Wednesday, July 11th. Barclays set a €100.00 ($116.28) price objective on Bayer and gave the company a “neutral” rating in a research note on Thursday, July 12th. Goldman Sachs Group set a €116.00 ($134.88) price objective on Bayer and gave the company a “buy” rating in a research note on Friday, July 13th. Jefferies Financial Group set a €110.00 ($127.91) target price on Bayer and gave the stock a “buy” rating in a research report on Friday, July 13th. Finally, Independent Research set a €105.00 ($122.09) target price on Bayer and gave the stock a “neutral” rating in a research report on Monday, July 16th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of €97.45 ($113.32).
BAYN opened at €69.94 ($81.33) on Friday. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: Preferred Stock
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.